Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 1 to 10 of 14

Publication Record

Connections

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.
Schmidt AF, Holmes MV, Preiss D, Swerdlow DI, Denaxas S, Fatemifar G, Faraway R, Finan C, Valentine D, Fairhurst-Hunter Z, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh K, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Lill CM, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott RA, Luan J, Bobak M, Malyutina S, Pająk A, Kubinova R, Tamosiunas A, Pikhart H, Grarup N, Pedersen O, Hansen T, Linneberg A, Jess T, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Lester KH, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, Scott R, Schofield P, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H, Lifelines Cohort authors, Christen T, Mook-Kanamori DO, ICBP Consortium, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dörr M, Lerch MM, Völker U, Völzke H, Ward J, Pell JP, Meade T, Christophersen IE, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Roussel R, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Hopewell JC, Seshadri S, METASTROKE Consortium of the ISGC, Dale C, Costa RPE, Ridker PM, Chasman DI, Reiner AP, Ritchie MD, Lange LA, Cornish AJ, Dobbins SE, Hemminki K, Kinnersley B, Sanson M, Labreche K, Simon M, Bondy M, Law P, Speedy H, Allan J, Li N, Went M, Weinhold N, Morgan G, Sonneveld P, Nilsson B, Goldschmidt H, Sud A, Engert A, Hansson M, Hemingway H, Asselbergs FW, Patel RS, Keating BJ, Sattar N, Houlston R, Casas JP, Hingorani AD
(2019) BMC Cardiovasc Disord 19: 240
MeSH Terms: Anticholesteremic Agents, Biomarkers, Brain Ischemia, Cholesterol, LDL, Down-Regulation, Dyslipidemias, Genome-Wide Association Study, Humans, Myocardial Infarction, Polymorphism, Single Nucleotide, Proprotein Convertase 9, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Serine Proteinase Inhibitors, Stroke, Treatment Outcome
Added March 24, 2020
0 Communities
1 Members
0 Resources
17 MeSH Terms
Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel.
Sturm AC, Knowles JW, Gidding SS, Ahmad ZS, Ahmed CD, Ballantyne CM, Baum SJ, Bourbon M, Carrié A, Cuchel M, de Ferranti SD, Defesche JC, Freiberger T, Hershberger RE, Hovingh GK, Karayan L, Kastelein JJP, Kindt I, Lane SR, Leigh SE, Linton MF, Mata P, Neal WA, Nordestgaard BG, Santos RD, Harada-Shiba M, Sijbrands EJ, Stitziel NO, Yamashita S, Wilemon KA, Ledbetter DH, Rader DJ, Convened by the Familial Hypercholesterolemia Foundation
(2018) J Am Coll Cardiol 72: 662-680
MeSH Terms: Apolipoproteins B, Expert Testimony, Genetic Counseling, Genetic Testing, Humans, Hyperlipoproteinemia Type II, Proprotein Convertase 9, Receptors, LDL
Added April 10, 2019
0 Communities
1 Members
0 Resources
8 MeSH Terms
Reply to Ward and Colleagues' Comment on "Using Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors".
Jerome RN, Pulley JM, Roden DM, Shirey-Rice JK, Bastarache LA, Bernard G, Ekstrom L, Lancaster WJ, Denny JC
(2018) Drug Saf 41: 1101
MeSH Terms: Humans, Proprotein Convertase 9
Added March 26, 2019
0 Communities
2 Members
0 Resources
MeSH Terms
Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.
Jerome RN, Pulley JM, Roden DM, Shirey-Rice JK, Bastarache LA, R Bernard G, B Ekstrom L, Lancaster WJ, Denny JC
(2018) Drug Saf 41: 303-311
MeSH Terms: Cholesterol, LDL, Enzyme Inhibitors, Female, Genotype, Humans, Hypercholesterolemia, Male, Phenotype, Polymorphism, Single Nucleotide, Product Surveillance, Postmarketing, Proprotein Convertase 9, Risk Factors, Spinal Dysraphism
Added March 14, 2018
0 Communities
2 Members
0 Resources
13 MeSH Terms
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, Hartwig FP, Horta BL, Hyppönen E, Power C, Moldovan M, van Iperen E, Hovingh GK, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Liu T, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott R, Luan J, Bobak M, Malyutina S, Pająk A, Kubinova R, Tamosiunas A, Pikhart H, Husemoen LL, Grarup N, Pedersen O, Hansen T, Linneberg A, Simonsen KS, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Kirchner HL, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H, LifeLines Cohort study group, Christen T, Mook-Kanamori DO, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dörr M, Lerch MM, Völker U, Völzke H, Ward J, Pell JP, Smith DJ, Meade T, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Balkau B, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Ridker PM, Chasman DI, Reiner AP, Lange LA, Ritchie MD, Asselbergs FW, Casas JP, Keating BJ, Preiss D, Hingorani AD, UCLEB consortium, Sattar N
(2017) Lancet Diabetes Endocrinol 5: 97-105
MeSH Terms: Blood Glucose, Case-Control Studies, Cholesterol, LDL, Cohort Studies, Diabetes Mellitus, Type 2, Genetic Predisposition to Disease, Genetic Variation, Humans, Mendelian Randomization Analysis, Proprotein Convertase 9, Randomized Controlled Trials as Topic
Added March 14, 2018
0 Communities
2 Members
0 Resources
11 MeSH Terms
Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms.
Tavori H, Giunzioni I, Predazzi IM, Plubell D, Shivinsky A, Miles J, Devay RM, Liang H, Rashid S, Linton MF, Fazio S
(2016) Cardiovasc Res 110: 268-78
MeSH Terms: Animals, Apolipoproteins E, Atherosclerosis, Cholesterol, LDL, Hepatocytes, Humans, Lipogenesis, Liver, Mice, Inbred C57BL, Mice, Knockout, Proprotein Convertase 9, Receptors, LDL, Triglycerides
Added February 3, 2017
1 Communities
1 Members
0 Resources
13 MeSH Terms
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy.
Feng Q, Wei WQ, Chung CP, Levinson RT, Bastarache L, Denny JC, Stein CM
(2017) Pharmacogenomics J 17: 204-208
MeSH Terms: Adult, African Americans, Aged, Biomarkers, Cholesterol, LDL, Dyslipidemias, European Continental Ancestry Group, Female, Gene Frequency, Genetic Association Studies, Genotype, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Pharmacogenetics, Pharmacogenomic Variants, Phenotype, Polymorphism, Single Nucleotide, Proprotein Convertase 9, Risk Factors, Treatment Outcome
Added March 14, 2018
0 Communities
1 Members
0 Resources
22 MeSH Terms
Local effects of human PCSK9 on the atherosclerotic lesion.
Giunzioni I, Tavori H, Covarrubias R, Major AS, Ding L, Zhang Y, DeVay RM, Hong L, Fan D, Predazzi IM, Rashid S, Linton MF, Fazio S
(2016) J Pathol 238: 52-62
MeSH Terms: Animals, Atherosclerosis, Disease Models, Animal, Flow Cytometry, Fluorescent Antibody Technique, Humans, Immunohistochemistry, Immunoprecipitation, Macrophages, Peritoneal, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Proprotein Convertase 9, Proprotein Convertases, Receptors, LDL, Serine Endopeptidases, Transplantation Chimera
Added February 3, 2017
1 Communities
2 Members
0 Resources
18 MeSH Terms
PCSK9 is a critical regulator of the innate immune response and septic shock outcome.
Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, Cirstea MS, Boyd JH
(2014) Sci Transl Med 6: 258ra143
MeSH Terms: Animals, Disease Models, Animal, Genetic Variation, Hep G2 Cells, Humans, Immunity, Innate, Lipopolysaccharides, Male, Mice, Inbred C57BL, Mice, Knockout, Proprotein Convertase 9, Proprotein Convertases, Serine Endopeptidases, Shock, Septic
Added January 20, 2015
0 Communities
1 Members
0 Resources
14 MeSH Terms
Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms.
Rashid S, Tavori H, Brown PE, Linton MF, He J, Giunzioni I, Fazio S
(2014) Circulation 130: 431-41
MeSH Terms: Animals, Apolipoproteins B, Caco-2 Cells, Cell Survival, Enterocytes, Humans, Hypertriglyceridemia, Intestinal Mucosa, Intestines, Mice, Inbred C57BL, Mice, Knockout, Proprotein Convertase 9, Proprotein Convertases, RNA, Small Interfering, Receptors, LDL, Serine Endopeptidases, Transcription, Genetic, Triglycerides
Added February 12, 2015
0 Communities
1 Members
0 Resources
18 MeSH Terms